Prognostic value of Murray law-based quantitative flow ratio after percutaneous coronary intervention
In brief
Low post-PCI flow ratios tracked 23% five-year event rates, versus 17%
Among 3,455 patients, those in the lowest post-PCI flow-ratio group had major cardiovascular events in 23.1% of cases over five years, compared with 17.2% in the highest group. The association supports using the measure to assess risk after stenting, but its limited ability to separate patients above or below one cutoff favors interpreting it as a continuous measure.
- Journal
- EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology (Q1)
- Published
- 2 November 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Rui Zhang, Jingjing Xu, Changdong Guan, Yao Jiang, Yanpu Shi, Shengxian Tu, et al.
- PMID
- 42975601
- DOI
- 10.4244/EIJ-D-26-00457
Why clinicians should know about it
- Picked for Cardiology and Cardiovascular Medicine (top studies of the week, 15 November 2026): Long-term post-PCI physiology and cardiovascular outcomes
Abstract
BACKGROUND: Post-percutaneous coronary intervention (PCI) physiological indices have prognostic relevance. Murray law-based quantitative flow ratio (μQFR) enables wire-free, rapid, single-view functional assessment, yet its long-term prognostic value after PCI remains incompletely established. AIMS: We sought to evaluate the prognostic value of post-PCI μQFR for long-term adverse outcomes. METHODS: This prespecified subgroup analysis of the FAVOR III China trial included 3,825 patients. All PCI-treated vessels with a reference diameter ≥2.5 mm and 50-90% diameter stenosis were analysed for offline post-PCI μQFR. The primary endpoint was 5-year major adverse cardiovascular events (MACE; including death from any cause, myocardial infarction, or ischaemia-driven revascularisation). RESULTS: Post-PCI μQFR was successfully analysed in 4,196 vessels from 3,455 patients, with similar distributions between the randomised treatment groups. At 5 years, a low post-PCI μQFR was associated with a higher incidence of MACE compared with the intermediate and high post-PCI μQFR tertiles (23.1% vs 19.0% vs 17.2%; p=0.001). Using the highest tertile (μQFR>0.95) as a reference, adjusted hazard ratios (aHR) were 1.08 (95% confidence interval [CI]: 0.87-1.34) for the intermediate tertile (0.92-0.95) and 1.30 (95% CI: 1.06-1.60) for the lowest tertile (μQFR ≤0.91). Using a receiver operating characteristic-derived cutoff, MACE occurred more frequently in patients with post-PCI μQFR <0.94 (22.3% vs 17.4%, aHR 1.23, 95% CI: 1.04-1.47; p=0.02) than in those with post-PCI μQFR ≥0.94. No significant interaction was observed between treatment strategy and post-PCI μQFR (p for interaction=0.23). CONCLUSIONS: Post-PCI μQFR distributions were similar between treatment groups, but lower values were associated with higher 5-year adverse event risk without significant treatment interaction. Its limited binary discrimination supports use as a continuous metric for post-PCI physiological risk stratification. (ClinicalTrials.gov: NCT03656848).
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.